Impaired cardiac uptake of meta-[123I]iodobenzylguanidine in parkinson's disease with autonomic failure

Acta Neurologica Scandinavica

Volumn 97, Issue 5, 1998, Pages 307-314

  Braune, S ^a   Reinhardt, M ^a   Bathmann, J ^a   Krause, T ^a   Lehmann, M ^a   Lucking C H ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Autonomic failure; Metaiodobenzylguanidine; Parkinson's disease; Postganglionic sympathetic neurons

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ADRENALIN; NORADRENALIN;

AGED; ARTICLE; AUTONOMIC DYSFUNCTION; AUTONOMIC NERVOUS SYSTEM FUNCTION; CARDIOVASCULAR RESPONSE; CATECHOLAMINE BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG UPTAKE; FEMALE; HEART SCINTISCANNING; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROLOGIC DISEASE; PARKINSON DISEASE; POSTGANGLIONIC NERVE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPATHETIC NERVE CELL;

EID: 0031922616     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.1998.tb05958.x     Document Type: Article

References (39)

1. BANNISTER R, OPPENHEIMER DR. Degenerative diseases of the nervous system associated with autonomic failure. Brain 1972: 95: 457-74.
2. MATTHEWS MR. Autonomic ganglia in multiple system atrophy and pure autonomic failure. In: BANNISTER R, MATHIAS CJ, eds. Autonomic failure, 3rd edn, Oxford Medical Publications, 1992: 593-621.
3. POLINSKY RJ, KOPIN IJ, EBERT MH, WEISE V. Pharmacologic distinction of different orthostatic hypotension syndromes. Neurology 1981: 31: 1-7.
4. COHEN J, LOW PA, FEALEY RD, SHEPS S, JIANG NS. Somatic and autonomic function in progressive autonomic failure and multiple system atrophy. Ann Neurol 1987: 22: 692-9.
5. OPPENHEIMER D. Lateral horn cells in progressive autonomic failure. J Neurol Sci 1980: 46: 393-404.
6. 123I] iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst 1994: 49: 81-4.
7. BRAUNE S, AUER A, SCHULTE-MÖNTING J, SCHWERBROCK S, LÜCKING CH. Cardiovascular parameters: sensitivity to detect autonomic dysfunction and influence of age and sex. Clin Auton Res 1996: 6: 3-15.
8. IMHOLZ BP, WIELING W, LANGEWOUTERS GJ, MONTFRANS GA. Continuous finger arterial pressure; utility in the cardiovascular laboratory. Clin Auton Res 1991: 1: 43-53.
9. PARATI G, CASADEI R, GROPELLI A, DI RIENZO M, MANCIA G. Comparison of finger and intra-arterial blood pressure monitoring in rest and during laboratory testing. Hypertension 1989: 13: 647-55.
10. SILKE B, SPIERS JP, BOYD E, GRAHAM E, MCPARLAND G, SCOTT ME. Evaluation of non-invasive blood pressure measurement by the Finapres method at rest and during exercise in subjects with cardiovascular insufficiency. Clin Auton Res 1994: 4: 49-56.
11. DA PRADA M, ZÜRCHER G. Simultaneous radioenzymatic determination of plasma and tissue adrenaline, noradrenaline and dopamine within the fentomole range. Life Sci 1976: 16: 1161-74.
12. LEHMANN M, KEUL J. Capillary-venous difference of free plasma catecholamines at rest and during graded exercise. Eur J Appl Physiol 1985: 54: 502-5.
13. JAQUES S, TOBES MC, SISSON JC et al. Comparison of the sodium dependency of uptake of meta-iodobenzylguanidine and norepinephrine into cultured bovine adrenomedullary cells. Mol Pharmacol 1984: 26: 539-46.
14. GASNIER B, ROSIN MP, SCHERMAN D et al. Uptake of metaiodobenzylguanidine by bovine chromaffin granule membranes. Mol Pharmacol 1986: 29: 275-89.
15. 131I]metaiodobenzylguanidine: concise communication. J Nucl Med 1984: 22: 358-64.
16. SISSON JC, WIELAND DM, SHERMAN P, MANGER TJ, TOBES MC, JAQUES S. Metaiodobenzylguanidine as an index of the adrenergic nervous system integrity and function. J Nucl Med 1987: 27: 1620-4.
17. SISSON JC, SHAPIRO B, MEYERS L et al. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med 1987: 28: 1625-36.
18. SISSON JC, LYNCH JJ, JOHNSON J et al. Scintigraphic detection of regional disruption of adrenergic neurons in the heart. Am Heart J 1988: 116: 67-76.
19. DAE MW, O'CONNELL JW, BOTVINICK EH et al. Scintigraphic assessment of regional cardiac adrenergic innervation. Circulation 1989: 79: 634-44.
20. SOLANKI KK, BOMANJI J, MOYES J, MATHER SJ, TRAINER PJ, BRITTON KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled metaiodobenzylguanidine (MIBG). Nucl Med Commun 1992: 13: 513-21.
21. POTHOS E, DESMOND M, SULZER D. L-3,4-dihydroxyphenylalanine increases the quantal size of exocytotic dopamine release in vitro. J Neurochem 1996: 66 (2): 629-36.
22. LEHMANN M, PETERSEN KG, KHALAF AN. Sympathetic autonomic dysfunction. Programmed subcutaneous noradrenaline administration via microdosing pump. Klin Wochenschr 1991: 69: 872-9.
23. BANNISTER R, DAVIES B, HOLLY E, ROSENTHAL T, SEVER P. Defective cardiovascular reflexes and supersensitivity to sympathomimetic drugs in autonomic failure. Brain 1979: 102: 163-76.
24. SENARD JM, VALET P, DURRIEU G, BERLAN M, TRAN MA, MONTASTRUC JL. Adrenergic supersensitivity in Parkinsonians with orthostatic hypotension. Eur J Clin Invest 1990: 20: 613-19.
25. KREINER G, WOLZT M, MEGHADI S et al. Beurteilung der cardialen adrenergen Innervation bei Typ-I-Diabetikern mittels J-123 meta-Jodbenzylguanidin (MIBG) Szintigraphic - Diagnostische Bedeutung und Beziehung zur Ventrikel-funktion. Diabetes und Stoffwechsel 1992: 1: 201.
26. DIJK VAN JG, HAAN J, ZWINDERMAN K, KREMER B, VAN HILTEN BJ, Roos RAC. Autonomic nervous system dysfunction in Parkinson's disease: relationship with age, medication, duration and severity. J Neurol Neurosurg Psychiatry 1993: 56: 1090-5.
27. MICIELI G, MARTIGNONI E, CAVALLINI A, SANDRINI G, NAPPI G. Postprandial and orthostatic hypotension in Parkinson's disease. Neurology 1987: 37: 386-93.
28. TURKKA JT, TOLONEN U, MYLLYLÄ VV. Cardiovascular reflexes in Parkinson's disease. Eur Neurol 1987: 26: 104-12.
29. PFEIFER MA, COOK D, BODSKY J. Quantitative evaluation of cardiac parasympathetic activity in normal and diabetic man. Diabetes 1982: 31: 339-45.
30. HIRSCH EC. Why are nigral catecholaminergic neurons more vulnerable than other cells in Parkinson's disease? Ann Neurol 1992: 32: Suppl: S88-93.
31. HIRSCH EC. Does oxidative stress participate in nerve cell death in Parkinson's disease? Eur Neurol 1993: 33: Suppl 1: 52-9.
32. JENNER P, OLANOW CW. Pathological evidence for oxidative stress in Parkinson's disease and related degenerative disorders. In: Neurodegeneration and Neuroprotection in Parkinson's disease. Academic Press Ltd. 1996: 24-45.
33. GOTO S, HIRANO A. Catecholaminic neurons in the parabrachial nucleus of normal individuals and patients with idiopathic Parkinson's disease. Ann Neurol 1991: 30: 192-6.
34. HALLIDAY GM, LI YW, BLUMBERG PC et al. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. Ann Neurol 1990: 27: 374-85.
35. HARTOG JAGER DEN WA, BETHLEM J. The distribution of Lewy bodies in the central and the autonomic nervous system in idiopathic paralysis agitans. J Neurol Neurosurg Psychiatry 1960: 23: 283-90.
36. OHAMA E, IKUTA F. Parkinson's disease: Distribution of Lewy bodies and monoamine neuron system. Acta Neuropathol 1976: 34: 311-19.
37. HUNTER S. The rostral mesencephalon in Parkinson's disease and Alzheimer's disease. Acta Neuropathol 1985: 68: 53-8.
38. GOLDSTEIN DS, HOLMES C, CANNON RO, EISENHOFER G, KOPIN IJ. Sympathetic cardioneuropathy in dysautonomias. New Engl J Med 1997: 336(10): 696-702.
39. BENNARROCH EE, OPFER-GEHRKING TL, LOW PA. Use of the photoplethysmographic technique to analyze the Valsalva maneuver in normal man. Muscle Nerve 1991: 14: 1165-72.